查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球乳癌市場：按類型、治療類型、最終用戶和地區劃分的評估、機會和預測（2016-2030）
市場調查報告書
商品編碼
1388953

全球乳癌市場：按類型、治療類型、最終用戶和地區劃分的評估、機會和預測（2016-2030）

Breast Cancer Market Assessment, By Type, By Treatment Type, By End-user, By Region, Opportunities and Forecast, 2016-2030F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 207 Pages | 商品交期: 3-5個工作天內

價格

2022 年全球乳癌市場規模為 302 億美元，預計到 2030 年將達到 564 億美元，2023-2030 年預測期間複合年增長率為 8.1%。 由於全球乳癌盛行率不斷上升，預計乳癌市場將會成長。 據世界衛生組織稱，乳癌每年影響超過 230 萬人，使其成為成人中最常見的癌症。 乳癌盛行率的迅速增加是由於 BRAC1 和 BRAC2 等基因的先天突變以及荷爾蒙和生活方式的改變所致。 在癌症診斷和治療中採用人工智慧和機器學習演算法等多項先進技術有望在未來為乳癌帶來更好的結果，從而推動市場成長。

有助於乳癌早期檢測和更好治療的產品技術進步正在促進全球乳癌市場的成長。 此外，強大的新藥研發、政府和利害關係人為根除癌症所做的努力預計將推動全球乳癌市場的發展。 然而，人們對乳癌的認識不足、診療成本飆升以及新興國家基礎設施落後是全球乳癌市場面臨的問題。

2023年2月，吉利德科學公司宣布，美國食品藥物管理局（USFDA）診斷出不可切除的、局部晚期或轉移性HR（激素受體）陽性、HER2（人類表皮生長因子受體2））宣布批准 Trodelvy（sacituzumab govitecan-hziy）用於治療成年陰性乳癌患者。 該藥物用於已接受內分泌治療和至少兩種轉移性疾病全身性治療的患者。

本報告分析了全球乳癌市場，提供了產品概述、市場基本結構、整體市場規模趨勢展望、按細分市場和地區劃分的詳細趨勢、市場背景情況、我們正在調查影響因素、主要企業概況、市場佔有率等。

目錄

第 1 章研究方法

第 2 章專案範圍與定義

第 3 章新型冠狀病毒感染（COVID-19）對全球乳癌市場的影響

第 4 章執行摘要

第 5 章全球乳癌市場未來展望（2016-2030）

  • 市場規模與預測
    • 基於金額
    • 基於數量
  • 依類型
    • 乳管原位癌 (DCIS)
    • 浸潤性乳管癌 (IDC)
    • 小葉原位癌 (LCIS)
    • 浸潤性小葉癌 (ILC)
    • 三陰性乳癌
    • 發炎性乳癌 (IBC)
    • 轉移性乳癌
    • 懷孕期間罹患乳癌
    • 其他類型
  • 依治療類型
    • 手術
    • 放射治療
    • 化療
    • 荷爾蒙療法
      • 選擇性雌激素受體調節劑
      • 芳香□抑制劑
      • 減少雌激素受體表現的藥物
    • 標靶治療
      • Abemaciclib
      • Adotrastuzumab Emtansine
      • Everolimus
      • Trastuzumab
      • Ribociclib
      • Palbocicib
      • Pertuzumab
      • Olaparib
      • 其他
    • 免疫治療
    • 新輔助全身治療
    • 其他
  • 按最終用戶
    • 癌症研究
    • 醫院
    • 門診治療中心
    • 其他
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東/非洲
  • 各公司的市佔率（%，2022 年）

第 6 章全球乳癌市場未來展望：依地區劃分（2016-2030）

  • 北美*
    • 市場規模與預測
      • 基於金額
      • 基於數量
    • 依類型
    • 依治療類型
    • 按最終用戶
    • 美國*
      • 市場規模與預測
      • 依類型
      • 依治療類型
      • 按最終用戶
    • 加拿大
    • 墨西哥

為涵蓋的所有地區/國家提供每個細分市場的資訊。

  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 英國
    • 俄羅斯
    • 荷蘭
    • 西班牙
    • 土耳其
    • 波蘭
  • 南美洲
    • 巴西
    • 阿根廷
  • 亞太地區
    • 印度
    • 中國
    • 日本
    • 澳大利亞
    • 越南
    • 韓國
    • 印尼
    • 菲律賓
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第 7 章市場地圖（2022 年）

  • 依類型
  • 依治療類型
  • 按最終用戶
  • 按地區

第 8 章宏觀環境與產業結構

  • 需求與供給分析
  • 進出口分析（數量/價值基礎）
  • 供應/價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第 9 章市場動態

  • 生長促進因素
  • 抑製成長的因素（問題、限制）

第 10 章監理架構與創新

  • 臨床試驗
  • 專利情況
  • 監理機關的核准
  • 創新/新興技術

第 11 章主要公司狀況

  • 前 5 名市場領導者：競爭矩陣
  • 前 5 位市場領導者：市場收入分析（%，2022 年）
  • 併購 (M&A)/合資企業（如果適用）
  • SWOT 分析（針對 5 家進入市場的公司）
  • 專利分析（如果適用）

第 12 章價格分析

第 13 章案例研究

第 14 章主要公司展望

  • Merck & Co
    • 公司概況
    • 管理人員
    • 產品/服務
    • 財務狀況（據報告）
    • 重點市場與地域分佈
    • 近期趨勢
  • Bristol Myers Squibb
  • Kyowa Kirin
  • Eisai Co., Ltd.
  • Sanofi
  • Pfizer Inc
  • AstraZeneca
  • Novartis AG
  • Eli Lilly and Company
  • Genentech

上面列出的公司並非按市場份額排序，並且可能會根據研究工作中獲得的資訊進行更改。

第 15 章策略建議

第 16 章關於 Market Xcel，免責聲明

Product Code: MX10659

Global breast cancer market size was valued at USD 30.2 billion in 2022, and is expected to reach USD 56.4 billion in 2030, with a CAGR of 8.1% for the forecast period between 2023 and 2030F. The breast cancer market is expected to grow due to the increasing prevalence of breast cancer across the globe. According to WHO, more than 2.3 million cases of breast cancer occur each year, which makes it the most common cancer among adults. The surge in the prevalence of breast cancer can be attributed to inherited mutations in genes like BRAC1 and BRAC2, hormonal and lifestyle changes. Adoption of several advanced technologies, like artificial intelligence and machine learning algorithms, in cancer diagnosis and treatment is promising better outcomes for breast cancer in the future, fostering market growth.

Technological advancements in products that help in early detection and better treatment of breast cancer are contributing to the growth of the global breast cancer market. Additionally, a strong pipeline of new drugs, government and stakeholder efforts to eradicate cancer are anticipated to drive the global breast cancer market. However, lack of awareness about breast cancer, higher cost of diagnosis and treatment, and inadequate infrastructure in developing countries are some of the challenges for the global breast cancer market.

In February 2023, Gilead Sciences, Inc. announced that the United States Food and Drug Administration (USFDA) approved Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The drug is meant to be used for patients who have already received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.

Increasing Prevalence of Breast Cancer

Breast cancer is the most common cancer in females across the globe. Growing geriatric population, obesity, increased alcohol consumption, radiation exposure, family history of breast cancer, reproductive history, tobacco use, and postmenopausal hormone therapy are some of the factors that increase the risk of breast cancer. Adoption of a sedentary lifestyle is one of the major reasons behind the high prevalence of breast cancer. In recent years, the prevalence of breast cancer has increased significantly without any exception in developed and developing countries. As per sources from American Society of Clinical Oncology, 2,964,197 new female breast cancer cases are expected to occur in 2040, with a 31% increase from the corresponding 2,260,127 cases in 2020. Breast cancer ranks first among all types of cancer with around 12% share by number of cases.

Growing Preference for Targeted Therapy

Targeted therapy is meant to provide specialized treatment for breast cancer, with low adverse effects. It is highly effective as it mainly works on the proteins that cause cancer and promote neoplastic growth, sometimes even better than the effects of chemotherapy. A notable increase in procedures for targeted therapy has been observed in recent years due to increased survival rates, reduced resistance, and fewer side effects. Healthcare professionals are recommending the use of targeted therapy due to increased efficacy and better outcomes in breast cancer treatment.

For instance, in January 2023, Dr. Reddy's Laboratories Ltd. acquired the trademark for the breast cancer drug, Primcyv from Pfizer Products India Pvt Ltd for use in the Indian market. Primcyv is a targeted therapy for the treatment of breast cancer that targets HR+ and HER2 metastatic breast cancers. Strategic market developments promoting targeted therapy are anticipated to help in the better treatments of breast cancer and further boost the global breast cancer market.

Government Initiatives

Government organizations and agencies are actively promoting the treatment of breast cancer through awareness initiatives, thereby fostering market growth. Government initiatives such as research grants for cancer screening and research and laying favorable policies are fueling market growth. In 2021, National Cancer Institute in the United States invested USD 558.3 million for breast cancer research, and the Australian government invested USD 353.9 million as a part of the 2021-22 budget to support women's health in the country, including funding for cervical and breast cancer, endometriosis, and reproductive health . In January 2023, the government of the United Kingdom announced a EUR 10 million investment to develop 29 new breast cancer screening units. These units will be dedicated to reducing the burden of breast cancer in the United Kingdom. Such initiatives by the government and funding for breast cancer research, diagnosis, and treatment are anticipated to drive market growth for the global breast cancer market.

Advancement in Oncology

Oncology has witnessed remarkable advancements in the global breast cancer market, transforming cancer diagnosis and treatment. Innovations in molecular diagnostics, liquid biopsies, and next-generation sequencing technologies have improved early detection and personalized treatment approaches. Biomarker identification and companion diagnostic tests have enabled targeted therapies, enhanced patient outcomes, and reduced adverse effects. Additionally, artificial intelligence and machine learning algorithms have played a pivotal role in analyzing complex data, facilitating accurate diagnosis and predicting treatment responses. The rapid growth of this sector can be attributed to the strong inclination of physicians towards in-vitro diagnostics and novel innovations taking place in medical imaging for cancer diagnosis.

In November 2022, Google Health announced a financial agreement with iCAD, a leading market player focused on cancer detection and medical technology development. Through the partnership, iCAD can incorporate Google Health's mammography AI research model in its products for clinical usage. The advancement will help in better and more precise diagnosis of breast cancers.

Impact of COVID-19

The onset of the COVID-19 pandemic had a negative impact on the global breast cancer market. The market witnessed a significant dip due to preventive restrictions and lockdowns imposed by governments worldwide. Breast screening was reduced significantly which led to low procedure volumes and eventually impacting the market, negatively. Several surgeries and procedures were delayed or postponed due to the risk of contracting the virus in hospital. According to a study published in SAGE, in June 2022, a relative decline from 2019 to 2020 in breast cancer screening was observed, screening mammograms decreased by 44%. Although as an impact of COVID-19 pandemic, the promotion of telehealth, and utilization of artificial intelligence and machine learning created opportunity for several health-tech startups to develop innovative solutions for early diagnosis and prediction of breast cancer. Thus, the overall COVID-19 pandemic negatively affected the screening and treatment rate of breast cancer, however contributed to technological advancements.

Key Players Landscape and Outlook

Market players are using different strategies to broaden their product offerings and provide their users with access to a vast array of innovative and innovative products. To capture market share, organizations are diversifying their product offerings. To strengthen their market position, industry players use various growth strategies, such as partnerships, mergers and acquisitions, product launches, and manufacturing of new products.

In May 2022, Genentech launched a new combinational drug PHESGO - a combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase for breast cancer patients. The drug is expected to reduce the treatment cost by 20%.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19 on the Global Breast Cancer Market

4. Executive Summary

5. Global Breast Cancer Market Outlook, 2016-2030F

  • 1.1. Market Size & Forecast
    • 1.1.1. By Value
    • 1.1.2. By Volume
  • 1.2. By Type
    • 1.2.1. Ductal Carcinoma In Situ (DCIS)
    • 1.2.2. Invasive Ductal Carcinoma (IDC)
    • 1.2.3. Lobular Carcinoma In Situ (LCIS)
    • 1.2.4. Invasive Lobular Cancer (ILC)
    • 1.2.5. Triple Negative Breast Cancer
    • 1.2.6. Inflammatory Breast Cancer (IBC)
    • 1.2.7. Metastatic Breast Cancer
    • 1.2.8. Breast Cancer During Pregnancy
    • 1.2.9. Other Types
  • 1.3. By Treatment Type
    • 1.3.1. Surgery
    • 1.3.2. Radiation therapy
    • 1.3.3. Chemotherapy
    • 1.3.4. Hormonal therapy
      • 1.3.4.1. Selective Estrogen Receptor Modulators
      • 1.3.4.2. Aromatase Inhibitors
      • 1.3.4.3. Estrogen Receptor Downregulators
    • 1.3.5. Targeted Therapy
      • 1.3.5.1. Abemaciclib
      • 1.3.5.2. Adotrastuzumab Emtansine
      • 1.3.5.3. Everolimus
      • 1.3.5.4. Trastuzumab
      • 1.3.5.5. Ribociclib
      • 1.3.5.6. Palbocicib
      • 1.3.5.7. Pertuzumab
      • 1.3.5.8. Olaparib
      • 1.3.5.9. Others
    • 1.3.6. Immunotherapy
    • 1.3.7. Neoadjuvant systemic therapy
    • 1.3.8. Other
  • 1.4. By End-user
    • 1.4.1. Cancer Research Institutes
    • 1.4.2. Hospitals
    • 1.4.3. Ambulatory Care Centers
    • 1.4.4. Others
  • 1.5. By Region
    • 1.5.1. North America
    • 1.5.2. Europe
    • 1.5.3. Asia-Pacific
    • 1.5.4. South America
    • 1.5.5. Middle East & Africa
  • 1.6. By Company Market Share (%), 2022

6. Global Breast Cancer Market Outlook, By Region, 2016-2030

  • 6.1. North America*
    • 6.1.1. Market Size & Forecast
      • 6.1.1.1. By Value
      • 6.1.1.2. By Volume
    • 6.1.2. By Type
      • 6.1.2.1. Ductal Carcinoma In Situ (DCIS)
      • 6.1.2.2. Invasive Ductal Carcinoma (IDC)
      • 6.1.2.3. Lobular Carcinoma In Situ (LCIS)
      • 6.1.2.4. Invasive Lobular Cancer (ILC)
      • 6.1.2.5. Triple Negative Breast Cancer
      • 6.1.2.6. Inflammatory Breast Cancer (IBC)
      • 6.1.2.7. Metastatic Breast Cancer
      • 6.1.2.8. Breast Cancer During Pregnancy
      • 6.1.2.9. Other Types
    • 6.1.3. By Treatment Type
      • 6.1.3.1. Surgery
      • 6.1.3.2. Radiation therapy
      • 6.1.3.3. Chemotherapy
      • 6.1.3.4. Hormonal therapy
      • 6.1.3.4.1. Selective Estrogen Receptor Modulators
      • 6.1.3.4.2. Aromatase Inhibitors
      • 6.1.3.4.3. Estrogen Receptor Downregulators
      • 6.1.3.5. Targeted Therapy
      • 6.1.3.5.1. Abemaciclib
      • 6.1.3.5.2. Adotrastuzumab Emtansine
      • 6.1.3.5.3. Everolimus
      • 6.1.3.5.4. Trastuzumab
      • 6.1.3.5.5. Ribociclib
      • 6.1.3.5.6. Palbocicib
      • 6.1.3.5.7. Pertuzumab
      • 6.1.3.5.8. Olaparib
      • 6.1.3.5.9. Others
      • 6.1.3.6. Immunotherapy
      • 6.1.3.7. Neoadjuvant systemic therapy
      • 6.1.3.8. Other
    • 6.1.4. By End-user
      • 6.1.4.1. Cancer Research Institutes
      • 6.1.4.2. Hospitals
      • 6.1.4.3. Retail Pharmacies
      • 6.1.4.4. Online Pharmacies
      • 6.1.4.5. Ambulatory Care Centers
      • 6.1.4.6. Others
    • 6.1.5. United States*
      • 6.1.5.1. Market Size & Forecast
      • 6.1.5.1.1. By Value
      • 6.1.5.1.2. By Volume
      • 6.1.5.2. By Type
      • 6.1.5.2.1. Ductal Carcinoma In Situ (DCIS)
      • 6.1.5.2.2. Invasive Ductal Carcinoma (IDC)
      • 6.1.5.2.3. Lobular Carcinoma In Situ (LCIS)
      • 6.1.5.2.4. Invasive Lobular Cancer (ILC)
      • 6.1.5.2.5. Triple Negative Breast Cancer
      • 6.1.5.2.6. Inflammatory Breast Cancer (IBC)
      • 6.1.5.2.7. Metastatic Breast Cancer
      • 6.1.5.2.8. Breast Cancer During Pregnancy
      • 6.1.5.2.9. Other Types
      • 6.1.5.3. By Treatment Type
      • 6.1.5.3.1. Surgery
      • 6.1.5.3.2. Radiation therapy
      • 6.1.5.3.3. Chemotherapy
      • 6.1.5.3.4. Hormonal therapy
      • 6.1.5.3.4.1. Selective Estrogen Receptor Modulators
      • 6.1.5.3.4.2. Aromatase Inhibitors
      • 6.1.5.3.4.3. Estrogen Receptor Downregulators
      • 6.1.5.3.5. Targeted Therapy
      • 6.1.5.3.5.1. Abemaciclib
      • 6.1.5.3.5.2. Adotrastuzumab Emtansine
      • 6.1.5.3.5.3. Everolimus
      • 6.1.5.3.5.4. Trastuzumab
      • 6.1.5.3.5.5. Ribociclib
      • 6.1.5.3.5.6. Palbocicib
      • 6.1.5.3.5.7. Pertuzumab
      • 6.1.5.3.5.8. Olaparib
      • 6.1.5.3.5.9. Others
      • 6.1.5.3.6. Immunotherapy
      • 6.1.5.3.7. Neoadjuvant systemic therapy
      • 6.1.5.3.8. Other
      • 6.1.5.4. By End-user
      • 6.1.5.4.1. Cancer Research Institutes
      • 6.1.5.4.2. Hospitals
      • 6.1.5.4.3. Retail Pharmacies
      • 6.1.5.4.4. Online Pharmacies
      • 6.1.5.4.5. Ambulatory Care Centers
      • 6.1.5.4.6. Others
    • 6.1.6. Canada
    • 6.1.7. Mexico

All segments will be provided for all regions and countries covered:

  • 6.2. Europe
    • 6.2.1. Germany
    • 6.2.2. France
    • 6.2.3. Italy
    • 6.2.4. United Kingdom
    • 6.2.5. Russia
    • 6.2.6. Netherlands
    • 6.2.7. Spain
    • 6.2.8. Turkey
    • 6.2.9. Poland
  • 6.3. South America
    • 6.3.1. Brazil
    • 6.3.2. Argentina
  • 6.4. Asia-Pacific
    • 6.4.1. India
    • 6.4.2. China
    • 6.4.3. Japan
    • 6.4.4. Australia
    • 6.4.5. Vietnam
    • 6.4.6. South Korea
    • 6.4.7. Indonesia
    • 6.4.8. Philippines
  • 6.5. Middle East & Africa
    • 6.5.1. Saudi Arabia
    • 6.5.2. UAE
    • 6.5.3. South Africa

7. Market Mapping, 2022

  • 7.1. By Type
  • 7.2. By Treatment Type
  • 7.3. By End-user
  • 7.4. By Region

8. Macro Environment and Industry Structure

  • 8.1. Supply Demand Analysis
  • 8.2. Import Export Analysis - Volume and Value
  • 8.3. Supply/Value Chain Analysis
  • 8.4. PESTEL Analysis
    • 8.4.1. Political Factors
    • 8.4.2. Economic System
    • 8.4.3. Social Implications
    • 8.4.4. Technological Advancements
    • 8.4.5. Environmental Impacts
    • 8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 8.5. Porter's Five Forces Analysis
    • 8.5.1. Supplier Power
    • 8.5.2. Buyer Power
    • 8.5.3. Substitution Threat
    • 8.5.4. Threat from New Entrant
    • 8.5.5. Competitive Rivalry

9. Market Dynamics

  • 9.1. Growth Drivers
  • 9.2. Growth Inhibitors (Challenges, Restraints)

10. Regulatory Framework and Innovation

  • 10.1. Clinical Trials
  • 10.2. Patent Landscape
  • 10.3. Regulatory Approvals
  • 10.4. Innovations/Emerging Technologies

11. Key Players Landscape

  • 11.1. Competition Matrix of Top Five Market Leaders
  • 11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2022)
  • 11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 11.4. SWOT Analysis (For Five Market Players)
  • 11.5. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

  • 14.1. Merck & Co
    • 14.1.1. Company Details
    • 14.1.2. Key Management Personnel
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As reported)
    • 14.1.5. Key Market Focus & Geographical Presence
    • 14.1.6. Recent Developments
  • 14.2. Bristol Myers Squibb
  • 14.3. Kyowa Kirin
  • 14.4. Eisai Co., Ltd.
  • 14.5. Sanofi
  • 14.6. Pfizer Inc
  • 14.7. AstraZeneca
  • 14.8. Novartis AG
  • 14.9. Eli Lilly and Company
  • 14.10. Genentech

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

15. Strategic Recommendations

16. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 2. Global Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 3. Global Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 4. Global Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 5. Global Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 6. Global Breast Cancer Market Share, By Region, in USD Billion, 2016-2030F
  • Figure 7. North America Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 8. North America Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 9. North America Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 10. North America Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 11. North America Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 12. North America Breast Cancer Market Share, By Country, in USD Billion, 2016-2030F
  • Figure 13. United States Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 14. United States Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 15. United States Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 16. United States Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 17. United States Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 18. Canada Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 19. Canada Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 20. Canada Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 21. Canada Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 22. Canada Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 23. Mexico Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 24. Mexico Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 25. Mexico Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 26. Mexico Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 27. Mexico Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 28. Europe Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 29. Europe Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 30. Europe Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 31. Europe Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 32. Europe Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 33. Europe Breast Cancer Market Share, By Country, in USD Billion, 2016-2030F
  • Figure 34. Germany Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 35. Germany Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 36. Germany Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 37. Germany Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 38. Germany Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 39. France Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 40. France Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 41. France Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 42. France Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 43. France Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 44. Italy Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 45. Italy Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 46. Italy Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 47. Italy Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 48. Italy Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 49. United Kingdom Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 50. United Kingdom Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 51. United Kingdom Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 52. United Kingdom Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 53. United Kingdom Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 54. Russia Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 55. Russia Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 56. Russia Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 57. Russia Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 58. Russia Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 59. Netherlands Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 60. Netherlands Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 61. Netherlands Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 62. Netherlands Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 63. Netherlands Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 64. Spain Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 65. Spain Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 66. Spain Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 67. Spain Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 68. Spain Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 69. Turkey Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 70. Turkey Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 71. Turkey Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 72. Turkey Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 73. Turkey Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 74. Poland Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 75. Poland Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 76. Poland Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 77. Poland Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 78. Poland Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 79. South America Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 80. South America Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 81. South America Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 82. South America Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 83. South America Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 84. South America Breast Cancer Market Share, By Country, in USD Billion, 2016-2030F
  • Figure 85. Brazil Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 86. Brazil Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 87. Brazil Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 88. Brazil Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 89. Brazil Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 90. Argentina Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 91. Argentina Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 92. Argentina Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 93. Argentina Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 94. Argentina Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 95. Asia-Pacific Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 96. Asia-Pacific Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 97. Asia-Pacific Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 98. Asia-Pacific Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 99. Asia-Pacific Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 100. Asia-Pacific Breast Cancer Market Share, By Country, in USD Billion, 2016-2030F
  • Figure 101. India Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 102. India Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 103. India Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 104. India Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 105. India Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 106. China Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 107. China Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 108. China Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 109. China Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 110. China Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 111. Japan Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 112. Japan Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 113. Japan Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 114. Japan Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 115. Japan Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 116. Australia Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 117. Australia Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 118. Australia Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 119. Australia Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 120. Australia Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 121. Vietnam Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 122. Vietnam Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 123. Vietnam Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 124. Vietnam Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 125. Vietnam Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 126. South Korea Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 127. South Korea Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 128. South Korea Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 129. South Korea Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 130. South Korea Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 131. Indonesia Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 132. Indonesia Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 133. Indonesia Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 134. Indonesia Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 135. Indonesia Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 136. Philippines Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 137. Philippines Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 138. Philippines Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 139. Philippines Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 140. Philippines Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 141. Middle East & Africa Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 142. Middle East & Africa Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 143. Middle East & Africa Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 144. Middle East & Africa Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 145. Middle East & Africa Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 146. Middle East & Africa Breast Cancer Market Share, By Country, in USD Billion, 2016-2030F
  • Figure 147. Saudi Arabia Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 148. Saudi Arabia Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 149. Saudi Arabia Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 150. Saudi Arabia Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 151. Saudi Arabia Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 152. UAE Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 153. UAE Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 154. UAE Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 155. UAE Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 156. UAE Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 157. South Africa Breast Cancer Market, By Value, in USD Billion, 2016-2030F
  • Figure 158. South Africa Breast Cancer Market, By Volume, in Thousands, 2016-2030F
  • Figure 159. South Africa Breast Cancer Market Share, By Type, in USD Billion, 2016-2030F
  • Figure 160. South Africa Breast Cancer Market Share, By Treatment Type, in USD Billion, 2016-2030F
  • Figure 161. South Africa Breast Cancer Market Share, By End-user, in USD Billion, 2016-2030F
  • Figure 162. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 163. By Treatment Type Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 164. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2022